摘要
腹腔感染是ICU和住院患者第二大感染性疾病,病死率高达20%~30%.医学的进步并没有改善腹腔感染患者预后,且日益严峻的细菌耐药形势可能导致腹腔感染患者预后恶化.腹腔感染可导致肠道菌群失调,而肠道菌群失调反过来又可加重腹腔感染.肠道微生态制剂可调节肠道菌群,是腹腔感染潜在的治疗措施.笔者回顾腹腔感染时肠道菌群的变化、肠道菌群对腹腔感染预后的影响及肠道微生态制剂在腹腔感染中的作用,旨在为临床应用提供参考.
Intra-abdominal infection is the second common infectious disease in intensive care unit and inhospital patients,with the mortality rate of 20%-30%.Advances in medicine have not improved the outcomes of patients with intra-abdominal infection,and the increasing multi-drug resistance organism may lead to a deterioration in the prognosis of patients with intra-abdominal infection.Gut microbiota dysbiosis and abdominal cavity infections show an interdependent and mutually aggravating relationship.Intestinal microecological preparations regulate gut flora and are potential therapeutic measures for intra-abdominal infections.The authors review the changes in gut flora during intra-abdominal infection,the effect of gut flora on the prognosis of intra-abdominal infections and the role of intestinal microecological preparations in intra-abdominal infections.
作者
隆毅
吴桂新
陈梦婷
李蕊
李晓明
何永鹏
蒋正英
Long Yi;Wu Guixin;Chen Mengting;Li Rui;Li Xiaoming;He Yongpeng;Jiang Zhengying(Department of Critical Care Medicine,Chongqing University Cancer Hospital,Chongqing,400030,China;Department of Clinical Nutrition,Chongqing University Cancer Hospital,Chongqing,400030,China;Chongqing Key Laboratory of Translational Research for Cancer Metastasis and Individualized Treatment,Chongqing University Cancer Hospital,Chongqing,400030,China)
出处
《中华消化外科杂志》
CAS
CSCD
北大核心
2023年第11期1300-1305,共6页
Chinese Journal of Digestive Surgery
基金
重庆市自然科学基金(cstc2021jcyj-msxmX0400)
重庆市科研机构绩效激励引导专项(cstc2022jxjl120007)。
关键词
感染
腹腔
肠道菌群
益生菌
益生元
合生元
疗效
Infection
Abdominal cavity
Gut microbiota
Probiotics
Prebiotics
Synbiotics
Efficacy
